Dr. Lily Dara is a physician-scientist and hepatologist at the University of Southern California. Her work spans drug-induced liver injury (DILI) and autoimmune/cholestatic liver diseases. She trained in the laboratory of Dr. Neil Kaplowitz, investigating cell death pathways in hepatotoxicity, and established her independent research program with support from a Mentored Clinical Investigator Career Award from the NIDDK.

Her NIH-funded research focuses on immune-mediated liver side effects of cancer immunotherapy and checkpoint inhibitors, integrating mechanistic studies, animal models, and translational approaches, alongside work on autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). She serves as PI for the USC DILIN site, a member of the NIH LiverTox Expert Review Committee, and Vice Chair of the AASLD Cholestatic and Autoimmune Liver Disease Special Interest Group.